3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
32
Observational
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Melanoma
11
Lung Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasms
5
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Uncommon Pathological Types of Lung Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sexual Dysfunction, Physiological
1
Sarcopenia
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
NSCLC
1
Motor Activity
1
Lung Squamous Cell Carcinoma Stage IV
1
Lung Diseases, Interstitial
1
Liver Diseases
1
Kidney Neoplasms
1
Interventions
Surveys and Questionnaires
15
Radiosurgery
14
Magnetic Resonance Imaging
11
Magnetic Resonance Spectroscopy
10
Neuropsychological Tests
8
Radiotherapy
7
Radiation
4
Blood Specimen Collection
4
Patient Reported Outcome Measures
3
sacituzumab govitecan
2
Trastuzumab
2
Surgical Procedures, Operative
2
Quality of Life
2
Physical Examination
2
Phlebotomy
2
Perfusion Magnetic Resonance Imaging
2
Lead
2
Lapatinib
2
Interviews as Topic
2
Immunotherapy
2
Drug Therapy
2
Data Collection
2
Brain Mapping
2
Bevacizumab
2
Amplified Fragment Length Polymorphism Analysis
2
Aminolevulinic Acid
2
trastuzumab deruxtecan
1
pembrolizumab
1
osimertinib
1
lorlatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Brain Neoplasms
×
pembrolizumab
×
Clear all
NCT03458455
2023-11-01
TREATMENT
Oslo University Hospital
Unknown
200 enrolled